Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13337035 | 1.00 | DPP4 (0.39) | DPP4MMP1MMP2MMP8SMYD3 | |
| SCHEMBL13337051 | 0.96 | DPP4 (0.41) | DPP4MMP1MMP2MMP8SMYD3 | |
| SCHEMBL13337114 | 0.86 | MMP1 (0.37) | MMP1MMP2MMP8SMYD3DPP7 | |
| SCHEMBL24709908 | 0.84 | PREP (0.45) | DPP4MMP1MMP2MMP8JAK2 | |
| SCHEMBL25533933 | 0.83 | CYP1A2 (0.44) | DPP4 | |
| SCHEMBL25906054 | 0.82 | MMP1 (0.40) | MMP1MMP2MMP8JAK2JAK1 | |
| SCHEMBL25530419 | 0.81 | HRH3 (0.40) | DPP4 | |
| SCHEMBL13337038 | 0.81 | DPP7 (0.38) | DPP4MMP1MMP2MMP8DPP7 | |
| SCHEMBL13337060 | 0.80 | MMP1 (0.36) | MMP1MMP2MMP8SMYD3DPP7 | |
| SCHEMBL5493807 | 0.79 | CCR1 (0.43) | DPP4MMP1MMP2MMP8DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | OPRL1, CRH, OPRK1 | DPP4 300/4885MMP1 3090/4885MMP2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.